Nobody wants to partner with pmcb. Look at Semma they had Novartis years before clinical trials were to be expected yet pmcb can't attract anyone except unsuspecting retail investors.
2014 What makes Semma Therapeutics Fierce: The startup expects that it is a few years from having an implant that's ready for clinical testing. In fact, a recent $44 million Series A round is slated to get it into human proof-of-concept testing. MPM Capital led the round with participation from Fidelity Biosciences, Arch Venture Partners and Medtronic ($MDT). Novartis ($NVS) also invested and became a partner, although no specifics about the deal have been disclosed.
"Semma had the ability to partner with almost any pharma that we wanted," said Semma CEO Robert Millman in an interview with FierceMedicalDevices. "We look at Novartis as being a very good partner. Other companies may have more at-risk in diabetes, but Novartis has made a commitment to cell and gene therapy from research through development." Millman expects Semma will be able to tap into some of Novartis' resources in that area.
News 
Market Data 
Discover 
AI
